Matches in Wikidata for { <http://www.wikidata.org/entity/Q64039440> ?p ?o ?g. }
- Q64039440 description "article scientifique publié en 2019" @default.
- Q64039440 description "artículu científicu espublizáu n'abril de 2019" @default.
- Q64039440 description "im April 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q64039440 description "scientific article published on 25 April 2019" @default.
- Q64039440 description "wetenschappelijk artikel" @default.
- Q64039440 description "наукова стаття, опублікована у квітні 2019" @default.
- Q64039440 name "A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Typ" @default.
- Q64039440 name "A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Typ" @default.
- Q64039440 type Item @default.
- Q64039440 label "A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Typ" @default.
- Q64039440 label "A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Typ" @default.
- Q64039440 prefLabel "A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Typ" @default.
- Q64039440 prefLabel "A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Typ" @default.
- Q64039440 P1433 Q64039440-021BB880-24CD-4A9C-ACE0-F8067FB40590 @default.
- Q64039440 P1476 Q64039440-6FF6EA8F-A162-4033-9184-A3801A526EC4 @default.
- Q64039440 P2093 Q64039440-25CDA4D1-6D29-4013-BB3B-CD6104A72589 @default.
- Q64039440 P2093 Q64039440-64E9803C-0232-4032-96FA-09F75A2B15D5 @default.
- Q64039440 P2093 Q64039440-762C7F8A-24A2-4281-A60E-524C45C7D948 @default.
- Q64039440 P2093 Q64039440-77B4E425-060F-4766-8BEC-1202B0370CDB @default.
- Q64039440 P2093 Q64039440-A6B3E2E2-07AC-4B31-892E-B1E2AB27EEB0 @default.
- Q64039440 P2093 Q64039440-B2574DD2-C329-4A02-A445-BA402386F3B2 @default.
- Q64039440 P2093 Q64039440-B6623FA9-F8A1-4361-9EC1-DA5F46EE6DFC @default.
- Q64039440 P2093 Q64039440-CF475907-502A-4C04-A051-8DBE9FBBC288 @default.
- Q64039440 P2093 Q64039440-D9BDFCC5-53E4-45B3-B73D-EBB4504233DC @default.
- Q64039440 P2093 Q64039440-E1D5C903-DEA6-41F7-B70F-64620F3A5EEB @default.
- Q64039440 P2093 Q64039440-F82F136A-484A-4F18-BE64-284CD1D37798 @default.
- Q64039440 P2093 Q64039440-FE877642-E1B1-431A-892D-25019DB4A404 @default.
- Q64039440 P2860 Q64039440-20D020D7-5977-47FE-AD0B-33728951A84D @default.
- Q64039440 P2860 Q64039440-23FCFCC9-EB53-4558-BCAF-C6F19E6D8546 @default.
- Q64039440 P2860 Q64039440-389271C4-8D9B-4BEB-AC22-50232C07F0BC @default.
- Q64039440 P2860 Q64039440-49C652E6-42B9-4F85-8FB9-88B73F4C50AF @default.
- Q64039440 P2860 Q64039440-637DD8E4-2C75-4E80-8F0B-13C7397890C0 @default.
- Q64039440 P2860 Q64039440-6A5FFA07-10A1-47BD-86C9-52FB86E77514 @default.
- Q64039440 P2860 Q64039440-6D4C572A-17AB-468F-BBC0-E8260B756E76 @default.
- Q64039440 P2860 Q64039440-8F0AB61F-DD81-4E94-BA33-F59FCE97F1D8 @default.
- Q64039440 P2860 Q64039440-B1BD6553-4D0A-4449-88AB-12B0B3D4BFA4 @default.
- Q64039440 P2860 Q64039440-B56230AF-2162-4247-B38E-E9AE6C9B86FE @default.
- Q64039440 P2860 Q64039440-B6B56CD2-E479-4C41-9588-70C50433CCEC @default.
- Q64039440 P2860 Q64039440-C22C202E-0116-4204-B647-34C4463EAB48 @default.
- Q64039440 P2860 Q64039440-CEC7C95B-C326-4AB6-970C-0ACF9D8575E4 @default.
- Q64039440 P2860 Q64039440-D3B70FAB-30AF-482A-A1A4-0F7CE4F4089C @default.
- Q64039440 P2860 Q64039440-F3A1567D-3355-4C2F-811E-709A0255EE46 @default.
- Q64039440 P2860 Q64039440-F76A22D4-45A3-450E-8F84-B5D09EC9E337 @default.
- Q64039440 P304 Q64039440-DFD2ADF1-42B5-492E-A5F9-3B929AF3CAB8 @default.
- Q64039440 P31 Q64039440-69B78C4F-D18D-44EB-BF8E-A1976195EB66 @default.
- Q64039440 P356 Q64039440-E13CB6EF-D96C-4EA3-A594-851644D28F84 @default.
- Q64039440 P407 Q64039440-CAEA9792-B21F-467F-A1C2-86B3573CE63C @default.
- Q64039440 P433 Q64039440-783D6AFB-0C6E-420F-AFEF-52ABB70F18C4 @default.
- Q64039440 P478 Q64039440-F79F37DF-CD09-4AF7-80BC-4B00D8223F1F @default.
- Q64039440 P50 Q64039440-2037B35D-5687-4B61-9594-74929B145455 @default.
- Q64039440 P50 Q64039440-7EA4C1F0-5681-4B53-8E1B-6033B5ABFDEA @default.
- Q64039440 P50 Q64039440-8F530D5B-AFEA-4F50-B384-534F5BBAF479 @default.
- Q64039440 P577 Q64039440-48D8B43D-259F-4679-A670-CD85B68FA38A @default.
- Q64039440 P698 Q64039440-07BB874D-20E6-4F29-B404-6AE83B71D004 @default.
- Q64039440 P921 Q64039440-1CBFB742-0DBA-41AF-AD31-1330534F63DB @default.
- Q64039440 P921 Q64039440-985B5077-4F45-463A-8071-C03E1FFE49A0 @default.
- Q64039440 P921 Q64039440-B98BD732-008B-4493-956F-F2359E4E7177 @default.
- Q64039440 P921 Q64039440-F5D60C20-F2A2-496E-B1C5-115A99BC01DA @default.
- Q64039440 P921 Q64039440-F6CE09D3-BDA3-4E9E-8375-959DA17468CA @default.
- Q64039440 P932 Q64039440-133D24DB-5466-483A-99C5-5CFFB6A1A282 @default.
- Q64039440 P356 THEONCOLOGIST.2017-0664 @default.
- Q64039440 P698 31023863 @default.
- Q64039440 P1433 Q2122327 @default.
- Q64039440 P1476 "A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer" @default.
- Q64039440 P2093 "Blanca Cantos" @default.
- Q64039440 P2093 "Coralia Bueno-Muiño" @default.
- Q64039440 P2093 "Cristina Rodriguez-Antona" @default.
- Q64039440 P2093 "Eva Ciruelos" @default.
- Q64039440 P2093 "Juan-Antonio Guerra" @default.
- Q64039440 P2093 "Juan-Francisco Gonzalo" @default.
- Q64039440 P2093 "Juan-Luis Sanz" @default.
- Q64039440 P2093 "Juan-Manuel Sepúlveda" @default.
- Q64039440 P2093 "Luis Manso" @default.
- Q64039440 P2093 "Maria-Jose Echarri" @default.
- Q64039440 P2093 "Noelia Martinez-Jáñez" @default.
- Q64039440 P2093 "Santos Enrech" @default.
- Q64039440 P2860 Q28943314 @default.
- Q64039440 P2860 Q29615701 @default.
- Q64039440 P2860 Q35847455 @default.
- Q64039440 P2860 Q36243420 @default.
- Q64039440 P2860 Q36862832 @default.
- Q64039440 P2860 Q36940993 @default.
- Q64039440 P2860 Q37666056 @default.
- Q64039440 P2860 Q39243591 @default.
- Q64039440 P2860 Q40793437 @default.
- Q64039440 P2860 Q40914660 @default.
- Q64039440 P2860 Q44439251 @default.
- Q64039440 P2860 Q50262932 @default.
- Q64039440 P2860 Q56626150 @default.
- Q64039440 P2860 Q58874455 @default.
- Q64039440 P2860 Q64049797 @default.
- Q64039440 P2860 Q81776925 @default.
- Q64039440 P304 "e1024-e1033" @default.
- Q64039440 P31 Q13442814 @default.
- Q64039440 P356 "10.1634/THEONCOLOGIST.2017-0664" @default.
- Q64039440 P407 Q1860 @default.
- Q64039440 P433 "11" @default.
- Q64039440 P478 "24" @default.
- Q64039440 P50 Q61475065 @default.
- Q64039440 P50 Q80644307 @default.